Rup BJ - Search Results

1

Intratracheal administration of recombinant human factor IX (BeneFix) achieves therapeutic levels in hemophilia B dogs.

Russell KE, Read MS, Bellinger DA, Leitermann K, Rup BJ, McCarthy KP, Keith JC Jr, Khor SP, Schaub RG, Nichols TC. Russell KE, et al. Among authors: rup bj. Thromb Haemost. 2001 Mar;85(3):445-9. Thromb Haemost. 2001. PMID: 11307812

2

Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs.

Russell KE, Olsen EH, Raymer RA, Merricks EP, Bellinger DA, Read MS, Rup BJ, Keith JC Jr, McCarthy KP, Schaub RG, Nichols TC. Russell KE, et al. Among authors: rup bj. Blood. 2003 Dec 15;102(13):4393-8. doi: 10.1182/blood-2003-05-1498. Epub 2003 Aug 21. Blood. 2003. PMID: 12933577 Free article.

3

Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.

Brinkhous KM, Sigman JL, Read MS, Stewart PF, McCarthy KP, Timony GA, Leppanen SD, Rup BJ, Keith JC Jr, Garzone PD, Schaub RG. Brinkhous KM, et al. Among authors: rup bj. Blood. 1996 Oct 1;88(7):2603-10. Blood. 1996. PMID: 8839853 Free article.

4

Evaluation of recombinant human factor IX: pharmacokinetic studies in the rat and the dog.

Keith JC Jr, Ferranti TJ, Misra B, Frederick T, Rup B, McCarthy K, Faulkner R, Bush L, Schaub RG. Keith JC Jr, et al. Thromb Haemost. 1995 Jan;73(1):101-5. Thromb Haemost. 1995. PMID: 7740479

5

Preclinical studies of recombinant factor IX.

Schaub R, Garzone P, Bouchard P, Rup B, Keith J, Brinkhous K, Larsen G. Schaub R, et al. Semin Hematol. 1998 Apr;35(2 Suppl 2):28-32. Semin Hematol. 1998. PMID: 9565164 Review.

6

Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.

Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL; Recombinant Factor IX Study Group. Roth DA, et al. Blood. 2001 Dec 15;98(13):3600-6. doi: 10.1182/blood.v98.13.3600. Blood. 2001. PMID: 11739163 Free article. Clinical Trial.

7

Immune responses to recombinant factor IX (BeneFIX) and recombinant B domain deleted factor VIII (ReFacto).

Rup B. Rup B. Dev Biol (Basel). 2002;109:103-6. Dev Biol (Basel). 2002. PMID: 12434919 No abstract available.

8

Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial.

Schiffmann R, Goker-Alpan O, Holida M, Giraldo P, Barisoni L, Colvin RB, Jennette CJ, Maegawa G, Boyadjiev SA, Gonzalez D, Nicholls K, Tuffaha A, Atta MG, Rup B, Charney MR, Paz A, Szlaifer M, Alon S, Brill-Almon E, Chertkoff R, Hughes D. Schiffmann R, et al. J Inherit Metab Dis. 2019 May;42(3):534-544. doi: 10.1002/jimd.12080. Epub 2019 Apr 8. J Inherit Metab Dis. 2019. PMID: 30834538 Clinical Trial.

9

Immunogenicity and immune tolerance coagulation Factors VIII and IX.

Rup B. Rup B. Dev Biol (Basel). 2003;112:55-9. Dev Biol (Basel). 2003. PMID: 12762504

10

Anti-erythropoietin receptor (EPO-R) monoclonal antibodies inhibit erythropoietin binding and neutralize bioactivity.

D'Andrea AD, Rup BJ, Fisher MJ, Jones S. D'Andrea AD, et al. Among authors: rup bj. Blood. 1993 Jul 1;82(1):46-52. Blood. 1993. PMID: 7686789 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

32 results

Search Page

Filters